Health Care & Life Sciences » Pharmaceuticals | Boryung Pharmaceutical Co. Ltd.

Boryung Pharmaceutical Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,428
6,275
22,377
26,760
16,592
7,831
Total Accounts Receivable
99,440
109,965
130,212
135,445
144,314
130,703
Inventories
44,755
50,325
48,461
73,408
60,721
75,830
Other Current Assets
492
580
982
26,403
6,913
10,183
Total Current Assets
155,115
167,145
202,032
262,015
228,539
224,546
Net Property, Plant & Equipment
64,373
68,112
80,012
89,304
144,549
196,344
Total Investments and Advances
26,025
30,394
30,271
4,500
8,153
10,561
Intangible Assets
17,454
16,669
18,524
17,784
17,505
17,414
Other Assets
4,593
89
89
3,285
1,379
-
Total Assets
267,560
282,409
330,928
397,901
402,516
451,608
ST Debt & Current Portion LT Debt
31,685
34,550
56,071
25,518
38,888
Accounts Payable
20,115
18,328
25,431
38,788
42,172
Income Tax Payable
4,214
4,674
5,352
29,051
-
Other Current Liabilities
33,853
30,259
32,542
102,248
35,137
Total Current Liabilities
89,867
87,810
119,397
195,605
116,197
Long-Term Debt
-
2,482
1,250
-
27,400
Provision for Risks & Charges
8,570
10,138
9,270
4,767
7,161
Deferred Taxes
3,622
3,642
2,886
21,012
2,391
Other Liabilities
5,521
981
2,185
2,180
2,104
Total Liabilities
107,580
105,053
134,988
202,552
152,862
Common Equity (Total)
159,980
177,356
195,940
195,349
249,654
Total Shareholders' Equity
159,980
177,356
195,940
195,349
249,654
Total Equity
159,980
177,356
195,940
195,349
249,654
Liabilities & Shareholders' Equity
267,560
282,409
330,928
397,901
402,516

About Boryung Pharmaceutical Co.

View Profile
Address
Boryung Building
Seoul SL 03127
Korea, Republic Of
Employees -
Website http://www.boryung.co.kr
Updated 07/08/2019
Boryung Pharmaceutical Co., Ltd. engages in the manufacture of of drug products. Its main products include Kanarb, Dukarb, Tuvero, TODULA, BESTO, and gelfosM. Its products include cardiovascular, antibiotics, anticancer, amino acid, cosmetics, gastrointestinal, and API.